Predictive Oncology (NASDAQ: POAI), a data and
artificial-intelligence- (“AI”) driven, discovery-services company, possesses a
unique advantage over its competition in the form of samples and access to
historical data on clinical outcomes. This data could enable POAI to produce
value to pharmaceutical companies significantly faster than its competitors. An
article discussing the company reads, “Specifically, POAI can leverage two
unique proprietary assets, from its acquisition of Helomics, which virtually
eliminate development risk, a factor that considerably weighs on competitors’
efforts in the precision medicine space. First, Predictive Oncology possesses a
clinically validated, tumor-profiling platform built from data derived from
actual tumors collected from patients over more than 10 years, which was
clinically validated in ovarian cancer. Second, the company possesses data on
the drug-response profiles of over 150,000 tumors across 137 cancer types
tested over the same period. Using this valuable historical data, POAI’s
platform can help predict drug response and outcome of the specific type of
tumor collected from new patients, thus improving the patient outcomes.”
To view the full article, visit http://ibn.fm/iizsM
About Predictive Oncology
POAI is bringing precision medicine, or tailored medical
treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient-derived (PDx) smart tumor-profiling
platform to provide oncologists with a road map to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases to build AI-driven models of
tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise necessary
to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
